Risk Factors for Severe Influenza A Virus Pneumonia in Adult Cohort, Mexico, 2013–14

Alejandro Gómez-Gómez, Martin Magaña-Aquino, Sofia Bernal-Silva, Javier Araujo-Meléndez, Andreu Comas-García, Emma Alonso-Zúñiga, Eliana Torres-Torres, and Daniel E. Noyola

During the 2013–14 influenza season, we assessed characteristics of 102 adults with suspected influenza virus pneumonia in a hospital in Mexico; most were unvaccinated. More comorbidities and severity of illness were found than for patients admitted during the 2009–10 influenza pandemic. Vaccination policies should focus on risk factors.

During 2009, Mexico reported 3 outbreaks of influenza A(H1N1)pdm09 infection (1); during the 2011–12 winter, a fourth pandemic wave of illness attributed to the virus was reported (2). Many patients had severe pneumonia related to influenza A(H1N1)pdm09 virus; the death rate was higher in Mexico than in most countries (3–5).

Beginning December 5, 2013, admissions of adults with acute respiratory infections increased at Hospital Central “Dr Ignacio Morones Prieto” (Hospital Central), in San Luis Potosi, Mexico; 102 persons were admitted with suspected influenza pneumonia. A high proportion of patients required mechanical ventilation (MV) and intensive care. The number of acute respiratory infection–associated admissions of young children and older adults did not increase. This pattern, occurring nearly 5 years after the initial influenza A(H1N1)pdm09 outbreak, resembles that of the initial outbreak in San Luis Potosi in April 2009 (6). This raises questions regarding possible changes in the viral strain or the presence of large numbers of susceptible persons not exposed to, or vaccinated against, this virus. We analyzed characteristics of 102 patients with confirmed or suspected influenza pneumonia admitted during a 2-month period and compared them with those of 100 patients with confirmed A(H1N1)pdm09 infection hospitalized during the 2009–10 pandemic.

The Study

During December 5, 2013–February 7, 2014, 102 patients, 17–79 years of age, were admitted to Hospital Central with acute onset of cough or rhinorrhea plus dyspnea, fever, and radiographic evidence of pneumonia and were considered to have possible influenza-related pneumonia. We compared data for the 2013–14 cohort with data from patients 15–71 years of age with confirmed influenza A(H1N1)pdm09 infection admitted to Hospital Central during the 2009–10 pandemic (7). Patients were evaluated according to a clinical questionnaire (6,7); blood samples (laboratory tests and cultures), sputum samples or tracheal aspirates (Gram stain and culture), and chest radiographs were also evaluated. Nasopharyngeal or tracheal samples were analyzed to detect influenza virus by using real-time reverse transcription PCR (Laboratorio Estatal de Salud Pública, Servicios de Salud del Estado de San Luis Potosí) or sequence-specific primer PCR (Universidad Autónoma de San Luis Potosi) with previously reported primers (8). Empiric treatment (ceftriaxone and clarithromycin or ceftriaxone and levofloxacin) was administered, and a course of oseltamivir was started within 6 hours after admission at doses of 75–150 mg 2× daily.

Influenza A(H1N1)pdm09 virus was detected in 47 patients and influenza A (not subtyped) in 8 patients; samples were not submitted for virologic testing for 8 patients. In 28 (71.8%) of 39 patients with negative results by real-time and sequence-specific primer reverse transcription PCR, samples were collected >5 days after onset of symptoms or patients had received oseltamivir during ≥1 day at the time of sample collection; therefore, test results for those patients were not conclusive, and the patients were included in the cohort. Signs and symptoms of the remaining 11 patients with negative results and of the 8 untested patients were suggestive of influenza infection; therefore, they were included in the cohort.

Mean age of the 102 patients was 44.6 years; 52 (51%) were female, and 82 (80.4%) had risk factors for complications. The most common concurrent health conditions were obesity (63[62%]) and diabetes mellitus (23 [23%]). Eight (8%) patients had been vaccinated for 2013–14 seasonal influenza. Radiologic manifestations were bilateral ground glass opacities and consolidations. Most patients had severe illness; mean partial pressure arterial oxygen and fraction of inspired oxygen ratio (on admission was 175.6 (reference value 400; SD 74.4); 52 (50.9%) patients required MV.

Demographic and clinical characteristics of patients are shown in Table 1. The 52 patients receiving MV were...
Table 1. Characteristics of patients with severe pneumonia who required mechanical ventilation compared with patients who did not require mechanical ventilation, San Luis Potosí, Mexico, 2013–2014

| Characteristic                          | Without mechanical ventilation, n = 50 | With mechanical ventilation, n = 52 | p value |
|----------------------------------------|----------------------------------------|-------------------------------------|---------|
| Age, y, mean (SD)                      | 42.8 (13.8)                            | 46.2 (13.3)                         | 0.21    |
| Sex, no. (%)                           |                                        |                                     |         |
| M                                      | 25 (50)                                | 25 (48.1)                           | 0.21    |
| F                                      | 25 (50)                                | 27 (51.9)                           | 0.85    |
| Presence of ≥1 underlying condition, no. (%) |                                        |                                     |         |
| Obesity†                               | 38 (76)                                | 44 (84.6)                           | 0.27    |
| Diabetes mellitus                      | 12 (24)                                | 11 (21.2)                           | 0.73    |
| Immunosuppression‡                     | 4 (8)                                  | 5 (9.6)                             | 1.0     |
| Asthma-COPD-bronchiectasis             | 8 (16)                                 | 1 (1.9)                             | 0.01    |
| Other§                                 | 9 (18)                                 | 3 (5.8)                             | 0.06    |
| Underlying disorders, excluding obesity, no. (%) | 27 (54)                                | 21 (40.4)                           | 0.17    |
| Influenza vaccination during most recent season, no. (%) | 8 (16)                                 | 0                                    | 0.002   |
| Signs and symptoms, no. (%)            |                                        |                                     |         |
| Fever                                  | 49 (98)                                | 52 (100)                            | 0.49    |
| Headache                               | 45 (90)                                | 49 (94.2)                           | 0.48    |
| Cough                                  | 50 (100)                               | 52 (100)                            | NA      |
| Myalgias                               | 46 (92)                                | 46 (88.5)                           | 0.74    |
| Dyspnea                                | 50 (100)                               | 52 (100)                            | NA      |
| Blood-streaked sputum                  | 14 (28)                                | 15 (28.8)                           | 0.92    |
| Diarrhea                               | 9 (18)                                 | 6 (11.5)                            | 0.36    |
| Clinical findings, mean (SD)           |                                        |                                     |         |
| Body mass index†                       | 29.6 (4.8)                             | 31.9 (3.9)                          | 0.01    |
| Respiratory rate, bpm                  | 26.4 (3.3)                             | 30.3 (5)                            | <0.001  |
| Cardiac rate, bpm                      | 102.6 (12.4)                           | 109.2 (16.9)                        | 0.03    |
| Mean blood pressure, mm Hg             | 80.6 (11.3)                            | 74.2 (14.6)                         | 0.01    |
| Temperature, °C                        | 38.5 (0.5)                             | 38.5 (0.5)                          | 0.42    |
| PaO₂/FiO₂#                             | 236 (49.2)                             | 119.8 (43.8)                        | <0.001  |
| Laboratory findings, mean (SD)         |                                        |                                     |         |
| Total leukocytes, × 10⁶ cells/μL†      | 8.1 (4.3)                              | 7.4 (3.9)                           | 0.39    |
| Lymphocytes, × 10⁹ cells/μL†           | 1.2 (0.75)                             | 0.84 (0.64)                         | 0.01    |
| Platelet count, × 10⁹/μL†              | 223.5 (93.1)                           | 212.4 (125.4)                       | 0.62    |
| C-reactive protein, mg/dL†             | 12.9 (8.8)                             | 19.7 (11.6)                         | 0.001   |
| Lactate dehydrogenase, U/L#            | 406.8 (416.6)                          | 694.6 (547.4)                       | 0.006   |
| Creatine phosphokinase, U/L**          | 349.5 (760.1)                          | 575.9 (544.4)                       | 0.1     |
| Symptom onset                          |                                        |                                     |         |
| Duration of symptoms before dyspnea, d, mean (SD) | 2.8 (2.8)                             | 3.1 (3.3)                           | 0.67    |
| Dyspnea duration before admission, d, mean (SD) | 3.9 (2.8)                             | 3.7 (2.7)                           | 0.75    |
| Duration of symptoms before hospital admission, d, mean (SD) | 6.7 (3.8)                             | 6.8 (3.5)                           | 0.99    |

†Statistical analyses used included Fisher exact test, χ² test, and Student t test. COPD, chronic obstructive pulmonary disease; NA, not applicable; PaO₂/FiO₂, partial pressure arterial oxygen and fraction of inspired oxygen ratio.
†Body mass index >30. Data available for 100 patients.
‡Patients with autoimmune disorders (4 cases; 1 patient had undergone renal transplantation), HIV infection (3 cases), lymphoma (1 case), and chronic renal failure (1 case).
§Other disorders: cardiopathy (5 cases), Down syndrome (3 cases; 1 with cardiopathy), hypothyroidism (3 cases), pregnancy (1 case), and obstructive sleep apnea syndrome (1 case)
¶Data available for 98 patients.
#Data available for 93 patients.
**Data available for 91 patients.

More likely to be obese (body mass index [BMI] >30) than those who did not require it (76.5% versus 46.9%, respectively; p = 0.002). Lactate dehydrogenase concentrations (406.8 mg/dL versus 694.6 mg/dL; p = 0.006) and C-reactive protein level (12.9 mg/dL versus 19.7 mg/dL; p = 0.001) were higher in patients who required MV.

To assess severity of illness and possible associated factors, we compared characteristics of the 55 patients with confirmed influenza A infection and 100 patients with A(H1N1)pdm09 infection admitted during the 2009–10 pandemic (Table 2). Patients in the 2013–14 cohort were somewhat older and heavier than those in the 2009–10 cohort: mean age of patients admitted during 2009–10 was 38.9 y and that of patients admitted during 2013–14 was 46.1 y (p = 0.002; Figure 1). Mean BMI of the 2009–10 cohort was 28.9, versus 31.9 for the 2013–14 cohort (p<0.001). Mean partial pressure arterial oxygen and fraction of inspired oxygen ratio was not significantly different for the 2 groups; however, proportion of those needing MV was significantly higher in the 2013–14 cohort (36/55 [65.5%] than in the 2009–10 cohort (47/100 [47%]; p = 0.03).

By the time of this report, 29 of the 102 patients admitted during 2013–14 had died, 69 had been discharged, and
The following characteristics of the 2013–14 influenza season cohort could explain this demographic situation: 1) low vaccination coverage of high-risk populations; 2) differences in the size of the high-risk susceptible population; 3) high prevalence of diabetes mellitus and obesity; 4) antigenic drift; and 5) unusually low temperatures during the 2013–14 winter season. The severity of pneumonia cases (MV requirement, low lymphocyte counts, and high C-reactive protein concentrations) among those admitted during 2013–14, and 6% among those admitted during 2009–10 (p = 0.35). In contrast to findings with the 2009–10 cohort, duration of symptoms among the 2013–14 cohort at the time of admission did not appear to affect the outcome (Figure 2).

In Mexico, the first 3 influenza A(H1N1)pdm09 waves were characterized by a high proportion of hospitalizations among persons 5–9 years of age (1,9); in the fourth wave, the proportion of hospitalizations increased in young children and older adults (2). The 2013–14 influenza season data resemble those of the initial A(H1N1)pdm09 outbreak in the high number of severe cases among adults <80 years and, although this observation has been described in other pandemics (10), possible explanations for this epidemiologic pattern should be analyzed. The following characteristics
population for influenza vaccination policies should be assessed. The vaccination rate was substantially lower in patients who required MV compared with those who did not; the overall vaccination rate among hospitalized patients contrasts with the high vaccination rates reported recently in Mexico for high-risk groups (71.7%–101.9%) (11,12). The association between severe influenza infection and obesity has been increasingly documented since the 2009 pandemic (13). Therefore, this group should be included among persons at high risk for influenza complications and the BMI range of subjects that require vaccination should include not only those with morbid obesity, but also those weighing >30 kg/m².

To improve outcomes, additional measures could be implemented such as campaigns and educational programs for the public and physicians that advocate early diagnosis, treatment, and identification of influenza-associated complications. In summary, to establish appropriate preventive measures, the epidemiologic characteristics of influenza outbreaks should be used to identify risk factors for severe infections.

Acknowledgments

We thank authorities at the Hospital Central “Dr Ignacio Morones Prieto” and Facultad de Medicina, Universidad Autónoma de San Luis Potosí for their support.

Dr Gómez-Gómez is a pulmonologist at Hospital Central “Dr Ignacio Morones Prieto” in San Luis Potosí. His research interests include respiratory infections with a focus on influenza and tuberculosis.

References

1. Chowell G, Echevarria-Zuno S, Viboud C, Simonsen L, Tamerius J, Miller MA, et al. Characterizing the epidemiology of the 2009 influenza A/H1N1 pandemic in Mexico. PLoS Med. 2011;8:e1000436. http://dx.doi.org/10.1371/journal.pmed.1000436

2. Borja-Aburto VH, Chowell G, Viboud C, Simonsen L, Miller MA, Grajales-Muñiz C, et al. Epidemiological characterization of a fourth wave of pandemic A/H1N1 influenza in Mexico, winter 2011–2012: age shift and severity. Arch Med Res. 2012;43:563–70. http://dx.doi.org/10.1016/j.arcmed.2012.09.005

3. Simonsen L, Spreeuwenberg P, Lustig R, Taylor RJ, Fleming DM, Kroneman M, et al. Global mortality estimates for the 2009 influenza pandemic from the GLaMOR project: a modeling study. PLoS Med. 2013;10:e1001558. http://dx.doi.org/10.1371/journal.pmed.1001558

4. Charu V, Chowell G, Palacio-Mejia LS, Echeverria-Zuno S, Borja-Aburto VH, Simonsen L, et al. Mortality burden of the
A/H1N1 pandemic in Mexico: a comparison of deaths and years of life lost to seasonal influenza. Clin Infect Dis. 2011;53:985–93. http://dx.doi.org/10.1093/cid/cir644

5. Comas-García A, García-Sepúlveda CA, Méndez-de Lira JJ, Aranda-Romo S, Hernández-Salinas AE. Mortality attributable to pandemic influenza A (H1N1) 2009 in San Luis Potosí, Mexico. Influenza Other Respir Viruses. 2011;5:76–82. http://dx.doi.org/10.1011/j.1750-2659.2010.00187.x

6. Gómez-Gómez A, Magaña-Aquino M, García-Sepúlveda CA, Ochoa-Pérez UR, Falcón-Escobedo R, Comas-García A, et al. Severe pneumonia associated with pandemic (H1N1) 2009 outbreak, San Luis Potosí, Mexico. Emerg Infect Dis. 2010;16:27–34. http://dx.doi.org/10.3201/eid1601.090941

7. Lovato-Salas F, Matienzo-Serment L, Monjarás-Ávila C, Godoy-Lozano E, Comas-García A, Aguilar-Barragán M, et al. Pandemic influenza A(H1N1)2009 and respiratory syncytial virus associated hospitalizations. J Infect. 2010;61:382–90. http://dx.doi.org/10.1016/j.jinf.2010.08.008

8. World Health Organization. CDC protocol of realtime RTPCR for influenza A(H1N1). [cited 2014 Jan 15]. http://www.who.int/csr/resources/publications/swineflu/CDCRealtimeRTPCR_SwineH1Assay-2009_20090430.pdf

9. Centers for Disease Control and Prevention (CDC). Update: novel influenza A (H1N1) virus infections-worldwide, May 6, 2009. MMWR Morb Mortal Wkly Rep. 2009;58:453–8.

10. Miller MA, Viboud C, Balinska M, Simonsen L. The signature features of influenza pandemics. Implications for policy. N Engl J Med. 2009;360:2595–8. http://dx.doi.org/10.1056/NEJM p 0903906

11. Ropero-Álvarez AM, Kurtis HJ, Danovaro-Holliday MC, Ruiz-Matus C, Andrus JK. Expansion of seasonal influenza vaccination in the Americas. BMC Public Health. 2009;9:361. http://dx.doi.org/10.1186/1471-2458-9-361

12. Ropero-Álvarez AM, Whittembury A, Kurtis HJ, dos Santos T, Danovaro-Holliday MC, Ruiz-Matus C. Pandemic influenza vaccination: lessons learned from Latin America and the Caribbean. Vaccine. 2012;30:916–21. http://dx.doi.org/10.1016/ j.vaccine.2011.11.092

13. Mertz D, Hyong-Kim T, Johnstone J, Lam PP, Science M, Kuster SP, et al. Populations at risk of severe or complicated influenza illness: systematic review and meta-analysis. BMJ. 2013;347:f5061. http://dx.doi.org/10.1136/bmj.f5061

Address for correspondence: Alejandro Gómez-Gómez, Facultad de Medicina, Universidad Autónoma de San Luis Potosí–Internal Medicine. Avenida Venustiano Carranza 2405, Colonia Los Filtros, San Luis Potosí, México, 78210; email: agomez.cer@prodigy.net.mx

New Podcasts

• Quiet Moment around the Campfire: James Whistler cover art
• Bat Flight and Zoonotic Viruses
• In Memoriam: James Harlan Steele (1913—2013)
• Outbreaks of Kingella kingae Infections in Daycare Facilities
• Incorporating Research and Evaluation into Pandemic Influenza Vaccination Preparedness and Response
• Unraveling the Mysteries of Middle East Respiratory Syndrome Coronavirus
• Low-Incidence, High-Consequence Pathogens

EMERGING INFECTIOUS DISEASES

http://www2c.cdc.gov/podcasts/player.asp?f=8626456